209 related articles for article (PubMed ID: 14523276)
21. Incidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapine.
Martín-Carbonero L; Núñez M; González-Lahoz J; Soriano V
HIV Clin Trials; 2003; 4(2):115-20. PubMed ID: 12671779
[TBL] [Abstract][Full Text] [Related]
22. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection.
Sulkowski MS; Thomas DL; Chaisson RE; Moore RD
JAMA; 2000 Jan; 283(1):74-80. PubMed ID: 10632283
[TBL] [Abstract][Full Text] [Related]
23. Clinical characteristics of hepatitis B and C virus infections in HIV-infected patients.
Phuangchoei P; Chotiyaputta W; Chayakulkeeree M
J Med Assoc Thai; 2015 Mar; 98(3):226-31. PubMed ID: 25920291
[TBL] [Abstract][Full Text] [Related]
24. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection.
den Brinker M; Wit FW; Wertheim-van Dillen PM; Jurriaans S; Weel J; van Leeuwen R; Pakker NG; Reiss P; Danner SA; Weverling GJ; Lange JM
AIDS; 2000 Dec; 14(18):2895-902. PubMed ID: 11153671
[TBL] [Abstract][Full Text] [Related]
25. Risk factors for grade 3-4 liver enzyme elevation in HIV and hepatitis C coinfected patients on combination antiretroviral therapy.
Chihrin S; Antoniou T; Raboud J; Shen S; Govan V; Fletcher D; Rachlis A; Kovacs C; Crouzat F; Tilley D; Chang B; Saskin R; Loutfy MR
AIDS Patient Care STDS; 2007 Jul; 21(7):469-78. PubMed ID: 17651028
[TBL] [Abstract][Full Text] [Related]
26. Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors.
Dieterich DT; Robinson PA; Love J; Stern JO
Clin Infect Dis; 2004 Mar; 38 Suppl 2():S80-9. PubMed ID: 14986279
[TBL] [Abstract][Full Text] [Related]
27. Incidence and risk factors for rash in Thai patients randomized to regimens with nevirapine, efavirenz or both drugs.
Ananworanich J; Moor Z; Siangphoe U; Chan J; Cardiello P; Duncombe C; Phanuphak P; Ruxrungtham K; Lange J; Cooper DA
AIDS; 2005 Jan; 19(2):185-92. PubMed ID: 15668544
[TBL] [Abstract][Full Text] [Related]
28. Hepatotoxicity During Isoniazid Preventive Therapy and Antiretroviral Therapy in People Living With HIV With Severe Immunosuppression: A Secondary Analysis of a Multi-Country Open-Label Randomized Controlled Clinical Trial.
Ngongondo M; Miyahara S; Hughes MD; Sun X; Bisson GP; Gupta A; Kumwenda J; Lavenberg JA; Torres TS; Nyirenda M; Kidonge KK; Hosseinipour MC;
J Acquir Immune Defic Syndr; 2018 May; 78(1):54-61. PubMed ID: 29406428
[TBL] [Abstract][Full Text] [Related]
29. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy.
Wit FW; Weverling GJ; Weel J; Jurriaans S; Lange JM
J Infect Dis; 2002 Jul; 186(1):23-31. PubMed ID: 12089658
[TBL] [Abstract][Full Text] [Related]
30. Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy.
Núñez M; Lana R; Mendoza JL; Martín-Carbonero L; Soriano V
J Acquir Immune Defic Syndr; 2001 Aug; 27(5):426-31. PubMed ID: 11511818
[TBL] [Abstract][Full Text] [Related]
31. Efavirenz and nevirapine in HIV-1 infection : is there a role for clinical pharmacokinetic monitoring?
Dahri K; Ensom MH
Clin Pharmacokinet; 2007; 46(2):109-32. PubMed ID: 17253884
[TBL] [Abstract][Full Text] [Related]
32. Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients.
Labarga P; Soriano V; Vispo ME; Pinilla J; Martin-Carbonero L; Castellares C; Casado R; Maida I; Garcia-Gasco P; Barreiro P
J Infect Dis; 2007 Sep; 196(5):670-6. PubMed ID: 17674307
[TBL] [Abstract][Full Text] [Related]
33. Hcv coinfection, an important risk factor for hepatotoxicity in pregnant women starting antiretroviral therapy.
Snijdewind IJ; Smit C; Godfried MH; Nellen JF; de Wolf F; Boer K; van der Ende ME
J Infect; 2012 Apr; 64(4):409-16. PubMed ID: 22227465
[TBL] [Abstract][Full Text] [Related]
34. Prevalence of hepatitis B virus and hepatitis C virus co-infection with human immunodeficiency virus in Thai patients: a tertiary-care-based study.
Sungkanuparph S; Vibhagool A; Manosuthi W; Kiertiburanakul S; Atamasirikul K; Aumkhyan A; Thakkinstian A
J Med Assoc Thai; 2004 Nov; 87(11):1349-54. PubMed ID: 15825712
[TBL] [Abstract][Full Text] [Related]
35. Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort.
Law WP; Duncombe CJ; Mahanontharit A; Boyd MA; Ruxrungtham K; Lange JM; Phanuphak P; Cooper DA; Dore GJ
AIDS; 2004 May; 18(8):1169-77. PubMed ID: 15166532
[TBL] [Abstract][Full Text] [Related]
36. Liver injury in HIV-1-infected patients receiving non-nucleosides reverse transcriptase inhibitors-based antiretroviral therapy.
Li ZC; Li HJ; Dai LL; Gao YQ; Cai WP; Li HY; Huang XJ; Zhang T; Wu H
Chin Med J (Engl); 2010 Dec; 123(24):3587-90. PubMed ID: 22166636
[TBL] [Abstract][Full Text] [Related]
37. Incidence and risk factors for chronic elevation of alanine aminotransferase levels in HIV-infected persons without hepatitis b or c virus co-infection.
Kovari H; Ledergerber B; Battegay M; Rauch A; Hirschel B; Foguena AK; Vernazza P; Bernasconi E; Mueller NJ; Weber R
Clin Infect Dis; 2010 Feb; 50(4):502-11. PubMed ID: 20085465
[TBL] [Abstract][Full Text] [Related]
38. Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort.
Torti C; Lapadula G; Casari S; Puoti M; Nelson M; Quiros-Roldan E; Bella D; Pastore G; Ladisa N; Minoli L; Sotgiu G; Mazzotta F; Lo Caputo S; Di Perri G; Filice G; Tinelli C; Carosi G;
BMC Infect Dis; 2005 Jul; 5():58. PubMed ID: 16018804
[TBL] [Abstract][Full Text] [Related]
39. The impact of HBV or HCV infection in a cohort of HIV-infected pregnant women receiving a nevirapine-based antiretroviral regimen in Malawi.
Andreotti M; Pirillo MF; Liotta G; Jere H; Maulidi M; Sagno JB; Luhanga R; Amici R; Mancini MG; Gennaro E; Marazzi MC; Vella S; Giuliano M; Palombi L; Mancinelli S
BMC Infect Dis; 2014 Apr; 14():180. PubMed ID: 24708626
[TBL] [Abstract][Full Text] [Related]
40. Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity.
Ritchie MD; Haas DW; Motsinger AA; Donahue JP; Erdem H; Raffanti S; Rebeiro P; George AL; Kim RB; Haines JL; Sterling TR
Clin Infect Dis; 2006 Sep; 43(6):779-82. PubMed ID: 16912956
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
